The global supplement market is growing. That's the headline most brands want to lead with. But the more uncomfortable truth, flagged publicly by the CEO of Novonesis, one of the world's largest biotech and ingredient suppliers, is that weak US consumer sentiment is actively suppressing domestic dietary supplement sales. For brands that derive the bulk of their revenue from American consumers, that's not a footnote. That's a structural problem that needs to be priced into every forecast, acquisition conversation, and expansion decision you're making right now.
What Novonesis Actually Said, and Why It Matters
Novonesis, the Danish biotech group formed from the merger of Novozymes and Chr. Hansen, operates at the ingredient and probiotic supply level that feeds directly into finished supplement products. When their CEO identifies US consumer sentiment as a specific headwind for dietary supplement sales, it carries weight. This isn't a retail analyst reading macroeconomic tea leaves. This is someone watching purchase volumes move in real time across a supply chain that feeds some of the largest supplement brands on the planet.
The signal is precise: global supplement demand continues to trend upward, but the United States, historically the category's dominant growth engine, is softening. Consumers are pulling back. They're reprioritizing discretionary spending. And supplements, despite their strong health halo, are not immune to that pressure when household budgets tighten.
For US-centric brands, this creates a concentration risk that may have been easy to ignore during the post-pandemic wellness boom. It's harder to ignore now.
The Global-US Divergence Is the Real Strategic Problem
Here's what makes this moment particularly difficult. If the entire market were contracting, brands could respond uniformly. Tighten margins, cut SKUs, focus on retention. But that's not what's happening. The divergence between global supplement growth and domestic US softness creates an asymmetric environment where your competitive position depends heavily on where your revenue actually comes from.
Brands with meaningful distribution in Europe, Asia-Pacific, or Latin America are insulated in a way that purely US-focused operators simply aren't. The same product, the same formulation, the same brand equity can generate growth internationally while stalling domestically. That gap is likely to widen before it narrows, particularly if US consumer confidence remains under pressure from inflation fatigue, labor market uncertainty, or continued interest rate effects on disposable income.
The strategic implication is direct: if you've been treating international expansion as a future-state priority, the Novonesis signal is a reason to accelerate that timeline. Europe's supplement market is growing, particularly in sports nutrition, functional health, and longevity-adjacent categories. Southeast Asia is maturing rapidly. Latin America, while more complex to navigate logistically, represents genuine volume opportunity for brands that move early.
Brands navigating this shift are also watching category adjacencies closely. NAD peptides and IV therapy are rewriting supplement demand in ways that suggest the highest-growth consumers are migrating toward premium, clinical-adjacent products. If your brand is anchored to mass-market supplement categories, the softness is likely more acute.
The $430 Billion Projection Assumes Something You Shouldn't Take for Granted
The supplement market is frequently cited as being on track to reach $430 billion globally by 2035. That number gets deployed constantly in pitch decks, investor materials, and category overviews as a reason to feel confident about the space. But that projection carries embedded assumptions, and the most critical one is that the United States continues to participate as the category's anchor market.
The US is not just the largest single supplement market by revenue. It's the market that sets pricing power benchmarks, drives innovation cycles, and signals product credibility to international buyers. If US consumer sentiment stays weak for an extended period, two things happen simultaneously. Category growth rates revise downward. And acquisition multiples for supplement brands, particularly those in exit conversations, come under pressure.
Private equity and strategic acquirers have been active in this space, drawn precisely by that $430 billion trajectory. But acquirers underwrite to revenue concentration and growth rate durability. A brand that derives 80% of its revenue from US consumers, in an environment where domestic sentiment is flagged by a tier-one ingredient supplier as a specific headwind, is a harder asset to price at premium multiples than it was 18 months ago.
If you're in exit conversations, or planning to be in the next 24 months, the Novonesis signal is worth factoring into how you're presenting geographic diversification and revenue resilience to potential acquirers. The story you tell about your international runway matters more now than it did before.
Consumer Behavior Shifts Are Accelerating the Pressure
It's not just macro sentiment. Consumer behavior within the supplement category is also evolving in ways that add complexity for brands dependent on traditional retail and direct-to-consumer channels in the US.
Subscription fatigue is real. Consumers who signed up for monthly supplement subscriptions during 2020 and 2021 have been churning at elevated rates as they reassess recurring expenses. The brands that built their revenue model heavily on subscription are feeling this acutely. Meanwhile, consumers who are still spending on supplements are increasingly gravitating toward products with clearer clinical backing, more transparent labeling, and stronger outcome specificity.
This behavioral shift connects to broader trends in how fitness-conscious consumers think about their health stack. The conversation has moved well beyond basic protein and multivitamins. Bone health, metabolic function, and longevity markers are driving new purchase decisions. Walking and weight training may not be enough for bone health, and consumers who understand that are actively looking for supplementation that fills the gap. Brands that can speak precisely to those outcomes are holding their position better than those competing on price alone.
At the same time, the channels through which consumers discover and purchase supplements are shifting. Gym-adjacent commerce, fitness professional recommendations, and practitioner-influenced purchasing are growing in influence. This is partly why companies like Altro Health are building infrastructure that lets trainers offer clinical-adjacent products directly to their clients. The retail shelf is losing ground to trust-based channels, and brands that can embed themselves in those channels have a meaningful advantage in a soft-sentiment environment.
What US-Centric Brands Should Actually Do
Acknowledging the headwind is step one. Acting on it is what separates brands that come through this period stronger from those that simply wait for sentiment to recover.
Here's where focused action makes sense:
- Audit your revenue concentration now. If more than 60-70% of your revenue comes from US consumers, you have concentration risk that investors, acquirers, and your own planning model should reflect. Quantify it explicitly.
- Build international distribution with urgency, not as a side project. Europe and Asia-Pacific aren't just growth markets. In this environment, they're risk mitigation. Find distribution partners, navigate regulatory requirements, and allocate real budget to the effort.
- Sharpen your clinical and outcome narrative. In a tighter spending environment, consumers are prioritizing supplements they believe actually work. Vague wellness positioning is losing to specific, substantiated claims. Invest in the science, then communicate it clearly.
- Reconsider your channel mix. If you're over-indexed to mass retail or pure DTC, explore gym channel partnerships, fitness professional affiliate programs, and practitioner recommendation pipelines. These channels maintain purchase intent even when broader consumer sentiment weakens.
- Stress-test your exit assumptions. If you're planning an exit in the next 24 months, model acquisition multiples under a scenario where US supplement growth underperforms the $430 billion trajectory by 15-20%. Know what that does to your valuation before you're in a room with a buyer who's already done that math.
The Brands That Will Navigate This Are Already Moving
The supplement brands best positioned for this environment share a few characteristics. They're not over-reliant on any single geography. They've built trust-based distribution channels that hold spending intent better than algorithmic advertising. And they've made product specificity, not broad wellness appeal, their core positioning.
The broader fitness and wellness industry is undergoing similar consolidation pressures. Connected strength equipment is the fastest-growing fitness segment, drawing discretionary spending that might otherwise go to supplements. And the boutique fitness sector has grown to $60.9 billion, representing a significant retail and recommendation channel for supplement brands that move to integrate with it effectively.
Weak US consumer sentiment is a real variable. The Novonesis CEO's comments make that harder to rationalize away. But it's a variable that brands with clear strategic vision can plan around. The ones who treat it as a data point, not an excuse, are the ones who'll come out of this period with better market position, more diversified revenue, and a stronger story to tell. Whether you're running a growing supplement brand or preparing it for acquisition, the time to act on that is now, not when sentiment recovers.